GeneDx (WGS) - 2024 Q1 - Quarterly Results

Exhibit 99.1 GeneDx Reports First Quarter 2024 Financial Results and Business Highlights Reported first quarter 2024 revenue from continuing operations of $61.5M with 96% year-over-year growth of exome and genome test revenue 1 Expanded first quarter 2024 adjusted gross margins from continuing operations to 61% 2 Narrowed first quarter 2024 adjusted net loss to$ 8.5M and delivered 71% year-over-year cash burn reduction 2 Raised guidance to deliver between $235M and$ 245M in FY 2024 revenue and reiterate pat ...